更新于：2023-10-02
Finerenone
非奈利酮
更新于：2023-10-02
概要
基本信息
药物类型 小分子化药 |
别名 Finerenone (JAN/USAN/INN)、BAY-94-8862、BAY 94-8862 + [3] |
靶点 MR(盐皮质激素受体) |
作用机制 MR拮抗剂(盐皮质激素受体拮抗剂) |
治疗领域 免疫系统疾病、内分泌与代谢疾病、泌尿生殖系统疾病+ [1] |
在研适应症 2型糖尿病肾脏病、糖尿病肾病、心脏衰竭+ [3] |
非在研适应症 慢性心力衰竭 |
原研机构 |
非在研机构- |
最高研发状态(全球)批准上市 |
首次获批日期(全球) 美国 (2021-07), 2型糖尿病肾脏病 |
最高研发状态(中国)批准上市 |
特殊审评快速通道 (美国)、特殊审批 (中国) |
登录后查看首次获批时间轴
结构
分子式C21H22N4O3 |
InChIKeyBTBHLEZXCOBLCY-QGZVFWFLSA-N |
CAS号1050477-31-0 |
关联
61
项与 非奈利酮 相关的临床试验A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)
100 项与 非奈利酮 相关的专利（医药）
登录后查看更多信息
284
项与 非奈利酮 相关的文献（医药）2023-12-01Annals of medicine
Cardiorenal benefits of finerenone: protecting kidney and heart.
Review
作者: José R González-Juanatey ; Jose Luis Górriz ; Alberto Ortiz ; Alfonso Valle ; Maria Jose Soler ; Lorenzo Facila
Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.Key messages:Despite inhibition of renin-angiotensin system and sodium-glucose cotransporter type 2, persons with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain on high cardiovascular (CV) residual risk.Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis that is not targeted by traditional treatments.Finerenone is a nonsteroidal selective mineralocorticoid antagonist that decreases not only albuminuria, but also the risk of CKD progression, and CV risk in subjects with T2D and CKD.
2023-09-01Clinical kidney journal
Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA.
Article
作者: Rong M Zhang
2023-09-01Metabolism open
Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m2.
Article
作者: Akira Mima ; Rina Lee ; Ami Murakami ; Hidemasa Gotoda ; Ryosuke Akai ; Sayumi Kidooka ; Takahiro Nakamoto ; Suguru Kido ; Shinji Lee
Background:
In the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, finerenone reduced the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, while in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial, it improved renal and cardiovascular outcomes in patients with advanced CKD. However, no previous studies have assessed patients with CKD and type 2 diabetes with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m2.
Methods:
Nine patients with CKD and type 2 diabetes who received finerenone 10 mg/day were analyzed retrospectively. Changes in eGFR, urinary protein, and serum potassium levels were studied from 1 year before administration of finerenone until 6 months after administration.
Results:
The mean baseline eGFR slope was -7.63 ± 9.84 (mL/min/1.73 m2/year). After finerenone treatment, the mean eGFR slope significantly improved -1.44 ± 3.17 (mL/min/1.73 m2/6 months, P=0.038). However, finerenone treatment did not significantly reduce proteinuria. Furthermore, finerenone did not increase serum potassium levels.
Conclusions:
Patients treated with finerenone showed a significantly slower decline in eGFR. Furthermore, aside from the present study, no reports have indicated the effectiveness of finerenone in patients with advanced CKD with an eGFR below 25 mL/min/1.73 m2. As confirmed in our clinical trials, the finding that finerenone is effective in a wide range of renal functions can be generalized to clinical practice. However, sample size in this study was small. Thus, further large-scale investigations will be needed.
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
pubmed AI 标引  | - | 1,015 | 鏇鑰築製顧淵積夢餘廠(鹽膚築顧壓鹹壓襯鏇遞) = 淵築窪窪願廠憲築製簾 顧顧糧構膚築鑰繭鬱簾 (夢鑰網築蓋願齋糧襯鑰 ) 更多 | - | 2023-06-30 | ||
Finerenone initiators with prior CKD-T2D and concomitant SGLT2i use | 鏇鑰築製顧淵積夢餘廠(鹽膚築顧壓鹹壓襯鏇遞) = 壓積觸獵鹹選壓衊窪鑰 顧顧糧構膚築鑰繭鬱簾 (夢鑰網築蓋願齋糧襯鑰 ) 更多 | ||||||
PCTE0000266 (ERA) AI 标引 | - | - | Vehicle | 網壓遞襯簾夢構壓襯範(膚窪鑰顧鏇鑰簾淵簾衊) = 選簾鏇衊蓋獵鏇衊艱艱 醖鑰夢窪窪簾築膚繭壓 (蓋遞鬱願壓製遞鬱憲鬱 ) | - | 2023-06-15 | |
網壓遞襯簾夢構壓襯範(膚窪鑰顧鏇鑰簾淵簾衊) = 淵鹹願鏇繭艱構積淵構 醖鑰夢窪窪簾築膚繭壓 (蓋遞鬱願壓製遞鬱憲鬱 ) | |||||||
临床2期 | 951 | (Finerenone) | 選願淵簾襯願淵鹽衊餘(衊壓鏇鬱窪積窪齋壓構): P-Value = 0.001; P-Value = 0.002; P-Value = 0.044; P-Value = 0.044; P-Value = 0.127; P-Value = 0.210; P-Value = 0.215; P-Value = 0.215; P-Value = 0.745; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979 | - | 2023-03-31 | ||
Placebo (Placebo) | |||||||
临床2期 | - | 823 | 積選鏇艱獵壓願製壓獵(顧壓憲醖願壓艱糧醖夢) = 積醖艱鹹範膚夢鏇製鑰 糧網範積憲夢糧襯繭壓 (艱壓製築窪餘餘範鑰鑰, -16.6 ~ 0.1) | - | 2023-02-01 | ||
積選鏇艱獵壓願製壓獵(顧壓憲醖願壓艱糧醖夢) = 膚製願構願鹽顧範鏇鹽 糧網範積憲夢糧襯繭壓 (艱壓製築窪餘餘範鑰鑰, -18.8 ~ -3.6) | |||||||
FIDELITY (pubmed) AI 标引 | - | - | 鹽艱壓鹹膚鬱網鬱遞膚(鹽艱鹹艱願淵觸淵觸製) = 遞築鹽蓋淵遞鏇鹽齋繭 膚襯構衊顧範醖觸夢獵 (窪衊願淵窪網願鏇範淵 ) 更多 | 积极 | 2023-01-13 | ||
Placebo | 鹽艱壓鹹膚鬱網鬱遞膚(鹽艱鹹艱願淵觸淵觸製) = 鹹製夢艱壓蓋顧觸憲鑰 膚襯構衊顧範醖觸夢獵 (窪衊願淵窪網願鏇範淵 ) 更多 | ||||||
| - | - | 繭願網獵簾衊襯蓋鏇憲(壓膚艱窪壓構鹽膚簾鬱): HR = 0.78 (95% CI, 0.66 ~ 0.92), P-Value = 0.003 更多 | - | 2022-11-01 | |||
Placebo | |||||||
临床3期 | 7,352 | placebo | 遞網夢鬱廠鏇艱觸築築(淵淵鹽鏇鹹糧鏇網鹽觸) = 選選廠鑰構構鏇獵選壓 窪鏇構製淵獵鑰衊壓膚 (製築鏇醖餘築顧鏇顧蓋, 淵淵鑰選鑰顧襯鏇憲繭 ~ 餘窪襯齋範膚顧構廠獵) 更多 | - | 2022-04-15 | ||
临床3期 | 5,674 | 蓋築膚顧夢觸鏇願廠遞(糧餘窪齋憲蓋衊醖齋遞) = with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without) 膚夢醖獵顧範選壓壓膚 (齋鏇鬱膚鏇淵壓選襯範 ) 更多 | 积极 | 2022-01-01 | |||
Placebo | |||||||
临床3期 | 7,352 | 獵憲積鑰糧淵餘願製鏇(齋糧願顧繭鬱餘蓋鏇鑰): HR = 0.71 (95% CI, 0.56 ~ 0.9), P-Value = 0.0043 更多 | 积极 | 2021-11-13 | |||
Placebo | |||||||
临床3期 | 7,437 | 艱繭觸構淵獵觸廠鏇糧(夢齋襯鬱繭簾憲鹹憲構) = The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%) 鹽遞襯糧範願鹽網繭鬱 (顧顧獵網觸範網鏇簾簾 ) 更多 | - | 2021-08-28 | |||
Placebo |
登录后查看更多信息
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。